NRX Pharmaceuticals Regulatory Approval
NRx Pharmaceuticals received FDA approval for its Abbreviated New Drug Application (ANDA) for Preservative-Free Ketamine ahead of its November 10 goal date. The product is an American-manufactured formulation that eliminates the use of benzethonium chloride, a preservative the FDA has declined to designate as safe. The company aims to address the ongoing national shortage of ketamine using modern high-volume manufacturing technology in partnership with Nephron Pharmaceuticals.
“We are excited to bring Preservative-Free Ketamine to market and to give patients and their physicians an option for repeat treatments without the potential dangers of a preservative that has been classified as unacceptable for inclusion in multiple product categories by the US Food and Drug Administration.”
Jonathan Javitt, MD, MPH, the company’s Chairman and Chief Executive Officer